Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Cash from Financing Activities (2020 - 2026)

Immuneering's Cash from Financing Activities history spans 7 years, with the latest figure at $180760.0 for Q1 2026.

  • On a quarterly basis, Cash from Financing Activities fell 98.69% to $180760.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $213.0 million, a 1074.32% increase, with the full-year FY2025 number at $226.6 million, up 4172.32% from a year prior.
  • Cash from Financing Activities came in at $180760.0 for Q1 2026, up from -$357523.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $213.2 million in Q3 2025, with the low at -$357523.0 in Q4 2025.
  • Historically, Cash from Financing Activities has averaged $16.3 million across 5 years, with a median of $104272.0 in 2022.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 2556.14% in 2022 and later skyrocketed 101297.86% in 2023.
  • Year by year, Cash from Financing Activities stood at -$184677.0 in 2022, then skyrocketed by 104.24% to $7835.0 in 2023, then tumbled by 623.14% to -$40988.0 in 2024, then plummeted by 772.26% to -$357523.0 in 2025, then skyrocketed by 150.56% to $180760.0 in 2026.
  • Business Quant data shows Cash from Financing Activities for IMRX at $180760.0 in Q1 2026, -$357523.0 in Q4 2025, and $213.2 million in Q3 2025.